# A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

> **NCT04691154** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Liquidia Technologies, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Pulmonary Hypertension Due to Lung Diseases

## Interventions

- **COMBINATION_PRODUCT:** L606 inhalation suspension

## Key facts

- **NCT ID:** NCT04691154
- **Lead sponsor:** Liquidia Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2025-03-20
- **Final completion:** 2031-03-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- PPD Development, LP

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691154, "A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04691154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*